-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
About Type 2 diabetes mellitus (T2DM) patients prospectively heart blood vessels results (CV) outcome trials support the use of sodium - glucose cotransporter 2 inhibitor (SGLT2i) T2DM patients to reduce cardiovascular event risk
.
The CVD-REAL Catalonia trial is a retrospective cohort study that uses real-world data collected daily from 2013 to 2016 to compare SGLT2i and other new users of hypoglycemic drugs (oGLD).
The risk of vascular events
.
According to the propensity score, new users of matched SGLT2i and oGLD were included in a ratio of 1:1
.
The incidence and risk ratio (HR) of all-cause mortality, heart failure hospitalization, chronic kidney disease, and adjusted major adverse CV events (MACE; all-cause mortality, myocardial infarction or stroke ) were compared
.
Heart failure myocardial infarction stroke
The occurrence of various outcomes of the two groups of subjects
The occurrence of various outcomes of the two groups of subjectsAfter matching the propensity scores, each group included 12,917 new users
.
About 27% of the subjects had a history of cardiovascular disease
.
Each group included 12,917 new users with SGLT2i use and lower heart failure (HR 0.
Original source:
Original source:Real, J.
Cardiovascular and mortality benefits of sodium--glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.
Leave a message here
